Literature DB >> 31807797

[Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication].

E Rotsel1, U Pietsch2.   

Abstract

Ketoacidosis induced by sodium-glucose cotransporter‑2 inhibitors (SGLT-2i) is rare. If it occurs, it is a serious clinical condition which requires immediate and correct treatment. At the moment, the occurrence of a ketoacidotic crisis necessitates permanent removal of the SGLT-2i from the patient's medication. Clear recommendations concerning the timing of discontinuation of SGLT-2i prior to planned surgical interventions are lacking. The tendency towards the undesirable effects of the medication in stressful situations is impressive. Currently, SGLT-2i are recognized as established oral antidiabetics and are becoming more popular. Clinicians should be aware of and alert to the diagnosis of ketoacidosis with normal blood glucose measurements in diabetic patients showing unspecific symptoms under administration of SGLT-2i.

Entities:  

Keywords:  Diabetic ketoacidosis; Euglycemic ketoacidosis; New oral antidiabetics; SGLT‑2 inhibitors in anesthesia; Sodium-glucose cotransporter‑2 inhibitors

Mesh:

Substances:

Year:  2019        PMID: 31807797     DOI: 10.1007/s00101-019-00701-9

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  6 in total

Review 1.  Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.

Authors:  Sharon C Peacock; Julie A Lovshin; David Z I Cherney
Journal:  Anesth Analg       Date:  2018-02       Impact factor: 5.108

Review 2.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Authors:  Hiddo J L Heerspink; Bruce A Perkins; David H Fitchett; Mansoor Husain; David Z I Cherney
Journal:  Circulation       Date:  2016-07-28       Impact factor: 29.690

Review 3.  Islet α cells and glucagon--critical regulators of energy homeostasis.

Authors:  Jonathan E Campbell; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2015-04-07       Impact factor: 43.330

4.  Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting.

Authors:  Sharon C Peacock; Julie A Lovshin
Journal:  Can J Anaesth       Date:  2017-11-20       Impact factor: 5.063

5.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

6.  Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery.

Authors:  Aaron Lau; Simon Bruce; Erica Wang; Ron Ree; Kevin Rondi; Anthony Chau
Journal:  Can J Anaesth       Date:  2017-11-22       Impact factor: 5.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.